Equities

Inhibrx Biosciences Inc

INBX:NSQ

Inhibrx Biosciences Inc

Actions
  • Price (USD)13.94
  • Today's Change-0.10 / -0.71%
  • Shares traded68.46k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.

  • Revenue in USD (TTM)1.73m
  • Net income in USD1.64bn
  • Incorporated2024
  • Employees166.00
  • Location
    Inhibrx Biosciences Inc11025 N. Torrey Pines Road, Suite 140LA JOLLA 92037United StatesUSA
  • Phone+1 (858) 795-4220
  • Fax+1 (302) 636-5454
  • Websitehttps://inhibrx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Scilex Holding Co50.83m-171.53m105.77m113.00------2.08-1.40-1.400.4425-1.770.44015.221.55484,123.80-102.93------68.24---233.88--0.1853-3.72----22.90---614.67------
Procaps Group SA414.10m52.20m125.23m5.50k2.133.181.800.30240.52090.52094.160.34910.8541.873.3875,290.1810.77--19.01--55.04--12.61--0.9861--0.8829--0.0434--142.18------
Telomir Pharmaceuticals Inc0.00-22.96m132.36m1.00--299.40-----0.8145-0.81450.000.01490.00----0.00-721.99---1,752.70-------------2.060.00-------1,430.39------
Puma Biotechnology Inc243.57m23.24m142.35m185.006.112.004.090.58450.4750.4755.031.451.1517.915.831,316,589.0010.95-12.2118.85-20.5369.2978.789.54-11.791.403.610.5234--3.34-1.251,079,450.00--83.41--
Elutia Inc24.78m-60.29m152.07m54.00------6.14-2.10-1.840.8695-1.160.48132.828.52458,925.90-117.08-42.93-649.22-79.3442.4143.32-243.28-64.160.849-1.18-----49.69-8.71-25.39--12.74--
LifeVantage Corp196.01m4.13m164.83m217.0041.235.9321.710.84090.31920.319215.272.223.062.5071.64903,290.306.469.9510.1715.5579.2181.452.113.080.9923559.360.0026.95-6.20-2.4015.63-16.94-2.18--
Scpharmaceuticals Inc30.28m-80.12m173.10m135.00--5.64--5.72-1.91-1.910.74170.61370.2620.72684.52224,281.50-69.31-38.23-78.18-42.3169.72---264.60-1,360.166.89-8.420.6246-------48.79------
Mediwound Ltd20.14m-19.97m180.78m100.00--8.71--8.98-2.16-2.162.181.920.33115.536.55201,410.00-32.83-24.48-49.28-32.9213.2543.27-99.17-38.431.51-3.260.2623---29.4840.6065.73--64.66--
Inhibrx Biosciences Inc1.73m1.64bn202.37m166.000.1171.130.123116.71119.47119.470.049912.330.0058--4.4110,445.78552.15-77.06637.71-93.91----94,778.95-1,590.91---45.760.00---17.88-26.85-66.20--26.30--
Biostem Technologies Inc210.39m14.32m219.71m67.0021.419.6515.111.040.63020.630210.581.403.828.465.01--26.03--135.75--94.84--6.81--1.2327.980.1576--------------
Lifecore Biomedical Inc128.45m5.71m257.05m524.00188.96--17.862.000.03690.05953.821.280.52172.014.96245,124.002.32-5.912.74-8.3334.6531.014.45-19.160.8030.1250.7641--24.20-25.46114.5334.47-16.72--
Precigen Inc3.96m-139.56m257.82m202.00--4.78--65.06-0.5479-0.54790.01540.18910.0289--5.4019,618.81-101.81-31.50-126.84-38.63-12.4444.00-3,521.68-232.32----0.00---76.87-47.16-20.22---48.30--
Eton Pharmaceuticals Inc34.68m-5.48m277.74m30.00--17.38--8.01-0.2135-0.21351.340.61861.039.447.631,155,900.00-16.27-46.22-29.44-58.2059.3072.16-15.81-76.861.41--0.2052--48.90--89.62--26.85--
Data as of Nov 21 2024. Currency figures normalised to Inhibrx Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

40.68%Per cent of shares held by top holders
HolderShares% Held
Viking Global Investors LPas of 30 Sep 20241.79m12.35%
Perceptive Advisors LLCas of 30 Sep 20241.06m7.35%
BlackRock Fund Advisorsas of 30 Sep 2024655.51k4.53%
Walleye Capital LLCas of 30 Sep 2024550.00k3.80%
The Vanguard Group, Inc.as of 30 Sep 2024512.59k3.54%
Slotnik Capital LLCas of 30 Sep 2024369.35k2.55%
Millennium Management LLCas of 30 Sep 2024289.36k2.00%
Geode Capital Management LLCas of 30 Sep 2024251.22k1.74%
Morgan Stanley & Co. LLCas of 30 Sep 2024208.91k1.44%
Caption Management LLCas of 30 Sep 2024200.00k1.38%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.